Chest
Clinical InvestigationsCyfra 21-1 as a Biologic Marker of Non-small Cell Lung Cancer: Evaluation of Sensitivity, Specificity, and Prognostic Role
Section snippets
Patients
One hundred sixty-one patients with lung cancer admitted to the Department of Chest Disease (University Hospital, Strasbourg, France) between March 1989 and June 1993 were prospectively entered in the study (Table 1). All had histologically and/or cytologically confirmed lung cancer. There were 72 with squamous cell carcinomas, 29 with adenocarcinomas, 15 with large cell carcinomas, and 45 with SCLC. Karnofsky performance status was noted and staging3 of NSCLC was done by clinical examination;
Reproductibility of Cyfra 21-1 Radiometric Assay
Reproductibility of determination of serume centrations was examined by measuring a control serum control in 13 different assays (interassay). The mean ± standard deviation and coefficient of variation was 3.67 ng/mL ± 0.41 and4.6%, respectively.
Cyfra 21-1 and Histology
The median (interquartile) serum Cyfra 21-1 in all NSCLC, squamous cell carcinoma, NSCLC other than squamous cell, and SCLC were 4.3 (2.05 to 16), 6.0 (2.55 to 19), 2.6 (1.25 to 9.75), and 1.7 (0.98 to 2.4) ng/mL, respectively. The median
Discussion
Our study confirms that Cyfra 21-1 is a both sensitive and specific tumor marker for NSCLC and especially for squamous cell carcinoma. It appears more sensitive and more specific than other tumor markers such as CEA, NSE, and slightly better than SCC in squamous cell carcinoma. The inability of Cyfra 21-1 to detect SCLC was also confirmed. The Cyfra 21-1 level in NSCLC correlates with the stage and, moreover, it appears as an independent prognostic factor along with performance status and stage.
Acknowledgments
We are grateful to Yolande Ledermann for excellent technical assistance.
References (26)
- et al.
Long-term survival and toxicity in small cell lung cancer: expanded Southwest Oncology Group experience
Chest
(1991) - et al.
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment
Int J Radiat Oncol Phys
(1991) - et al.
Neuro-specific-enolase in small cell lung cancer: longitudinal tumors marker evaluation
Lung Cancer
(1992) - et al.
The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells
Cell
(1982) - et al.
Histological evaluation or three new monoclonal anti-cytokeratin antibodies
Eur J Cancer Clin Oncol
(1987) - et al.
Value of CEA determination in biological fluids and tissues
Eur J Cancer Clin Oncol
(1987) Histopathology of lung cancer
Int J Epid
(1990)Histopathological typing of lung cancer: etiologic and epidemiologic features
Mc Vie JS, ed. Clinical and experimental pathology of lung cancer, developments in oncology 39. Boston: Martinus Nijhoff
(1986)A new international staging system for lung cancer
Chest
(1986)- et al.
Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients
J Clin Oncol
(1989)
Immunohistochemical localization of carcinoembryonic antigen, CEA-S, and nonspecific cross-reacting antigen in carcinomas of lung
Cancer
Serum neuron-specific enolase: a marker for disease extent and response to therapy for small cell lung cancer
Chest
Availability of tumor-antigen as a marker of squamous cell carcinoma of the lung and other organs
Cancer
Cited by (158)
Fusion expression, purification, and characterization of cytokeratin 19 fragments in E. coli for enhanced stability in diagnostic applications
2024, Protein Expression and PurificationImpedimetric immunosensors for detection of biomarkers
2022, The Detection of Biomarkers: Past, Present, and the Future ProspectsRecent advances in graphene-based nanobiosensors for salivary biomarker detection
2021, Biosensors and BioelectronicsCitation Excerpt :In this case, less than half of the analyzed studies provided a direct comparison with a gold standard (ELISA). CYFRA-21-1 is a cancer marker of new conception, found to be particularly useful in the detection of non-small cell lung cancer (Stieber et al., 1993; Wieskopf et al., 1995). Kumar and coworkers realized an electrochemical biosensor for the detection of CYFRA 21–1 using DPV (Kumar et al., 2016).
Cytokeratin 19 as a biomarker of highly invasive oral squamous cell carcinoma with metastatic potential
2020, Journal of Oral and Maxillofacial Surgery, Medicine, and PathologyCitation Excerpt :Over 20 different CKs have been identified, of which CK19 is the smallest member of the acidic type I CK family proteins [10,12]. Soluble CK19 fragments in circulation are widely used as a tumor marker in non-small cell lung cancer (NSCLC) [13–15]. Recent studies have shown that CK19 is expressed in various tumor tissues, including breast cancer, colon cancer, lung cancer, head and neck cancer (HNC) and hepatocellular carcinoma (HCC) [16–20].
Manuscript revision accepted November 4.